UMC Utrecht - GRIPonMASH

UMC Utrecht, short for University Medical Center Utrecht, is at the forefront of innovative medical research, patient care, and education. Renowned for its commitment to excellence, UMC Utrecht plays a pivotal role in shaping the future of healthcare.

As the coordinating institution for the GRIPonMASH project, UMC Utrecht showcases its dedication to advancing healthcare practices by addressing the challenge of reducing the disease burden associated with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). In the project, UMC Utrecht contributes by (1) developing personalized lifestyle advice for MASLD patients, (2) assessing potential economic, ethical, and regulatory barriers to the sustainability and scalability of the GRIPonMASH Platform and (3) project management.

This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101132946. The JU receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, Efpia, EuropaBio, MedTech Europe, Vaccines Europe and Mercodia Aktiebolag, Metadeq Limited and Julius Clinical Research BV.

Funded by the European Union, the private members, and those contributing partners of the IHI JU. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them.